Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

iVIEW Therapeutics Inc. is a clinical stage ophthalmology drug development company. Its lead compound iVIEW-1201 is starting global phase II human clinical trials in early 2019 for the treatment of viral conjunctivitis, which is an unmet medical need with no current FDA approved treatment. iVIEW was established by serial entrepreneurs and clinical physicians and funded by reputable VCs and strategic corporate investors. We are...
iVIEW Therapeutics Inc. is a clinical stage ophthalmology drug development company. Its lead compound iVIEW-1201 is starting global phase II human clinical trials in early 2019 for the treatment of viral conjunctivitis, which is an unmet medical need with no current FDA approved treatment. iVIEW was established by serial entrepreneurs and clinical physicians and funded by reputable VCs and strategic corporate investors. We are building a solid product pipeline with both clinical and pre-clinical assets through both in-house innovation research and global product in-licensing.

List your booth number for exhibitions, ask us